Logo

VMD

Viemed Healthcare, Inc.

VMD

Viemed Healthcare, Inc. • NASDAQ
$6.91 ▲ 0.44% (+0.03)
Market Cap $269.79 M
52w High $9.05
52w Low $5.93
Dividend Yield 0%
P/E 20.32
Volume 107.01K
Outstanding Shares 39.04M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $71.914M ▲ $35.703M ▲ $3.513M ▲ 4.885% ▼ $0.09 ▲ $13.181M ▲
Q2-2025 $63.056M ▲ $31.866M ▲ $3.157M ▲ 5.007% ▲ $0.08 ▲ $11.986M ▲
Q1-2025 $59.129M ▼ $29.438M ▼ $2.625M ▼ 4.439% ▼ $0.07 ▼ $10.454M ▼
Q4-2024 $60.695M ▲ $29.686M ▲ $4.316M ▲ 7.111% ▲ $0.11 ▲ $12.818M ▲
Q3-2024 $58.004M $28.743M $3.878M 6.686% $0.1 $12.132M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $11.123M ▼ $202.36M ▲ $66.865M ▲ $133.608M ▼
Q2-2025 $20.016M ▲ $184.603M ▲ $42.979M ▲ $139.731M ▲
Q1-2025 $10.16M ▼ $178.079M ▲ $41.33M ▼ $134.756M ▲
Q4-2024 $17.54M ▲ $177.069M ▲ $43.768M ▲ $131.393M ▲
Q3-2024 $11.347M $169.526M $42.731M $124.959M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $3.6M ▲ $18.367M ▲ $-32.297M ▼ $5.037M ▲ $-8.893M ▼ $10.731M ▲
Q2-2025 $3.157M ▲ $12.254M ▲ $-1.727M ▲ $-671K ▲ $9.856M ▲ $4.125M ▲
Q1-2025 $2.71M ▼ $2.854M ▼ $-8.53M ▲ $-1.704M ▼ $-7.38M ▼ $-12.629M ▼
Q4-2024 $4.424M ▲ $14.987M ▲ $-9.198M ▼ $404K ▲ $6.193M ▲ $3.158M ▲
Q3-2024 $3.905M $12.745M $-4.969M $-5.236M $2.54M $1.743M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Equipment Sales
Equipment Sales
 $20.00M ▲$10.00M ▼$10.00M ▲$20.00M ▲
Service
Service
 $10.00M ▲$10.00M ▲$10.00M ▲$10.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has been climbing at a steady pace over the past several years, and profits have remained positive throughout. Margins look reasonably healthy for a home-care focused healthcare company, helped by a service-heavy, high-touch model. Profitability did spike during the earlier pandemic period and then normalized to a lower, but still solid, level. Since then, earnings per share have been rebuilding gradually rather than explosively. Overall, this looks like a business that is growing in a measured way and staying consistently in the black, but not one that is chasing aggressive, high-risk expansion through its income statement.

Balance Sheet

Balance Sheet The balance sheet appears conservative and generally strengthening over time. Total assets and shareholder equity have grown steadily, indicating the company has been building its asset base and retaining value rather than relying heavily on borrowing. Debt is present but modest and relatively stable, suggesting financial leverage is controlled and not a central risk. Cash levels are not large but seem adequate for a company of this size, especially given ongoing access to operating cash flow. Overall, the financial foundation looks sound, with gradual improvement rather than dramatic swings.

Cash Flow

Cash Flow The company regularly generates cash from its operations, which is a key positive. A meaningful portion of that cash is consistently reinvested into equipment and related capital needs, which sometimes leaves free cash flow close to breakeven and other times in more comfortable positive territory. This pattern points to a business that is funding its own growth and maintaining or expanding its asset base, rather than simply harvesting cash. The trade-off is that reported free cash flow can look lumpy from year to year because of investment cycles, but under the surface, the engine of operating cash generation appears dependable.

Competitive Edge

Competitive Edge Viemed operates in a focused niche of home-based respiratory care, where it combines specialized clinical expertise with a high-touch service model. Its competitive position is supported by deep relationships with physicians, hospitals, and payers who value reduced hospital readmissions and better outcomes. The company’s regulatory and reimbursement know-how, along with a scalable home-care model, creates meaningful barriers for less specialized competitors. At the same time, it still competes in a broader field that includes larger durable medical equipment providers and healthcare systems, and it remains exposed to changes in reimbursement rules and competitive pricing. In short, Viemed’s niche is defensible and differentiated, but not immune to healthcare policy and competitive pressures.

Innovation and R&D

Innovation and R&D Innovation is a clear pillar of Viemed’s strategy. Its Viemed Engage platform ties together remote patient monitoring, telehealth, education, and data analytics into a single care hub, making its services more integrated and sticky for both patients and referring clinicians. The company is leaning into data-driven care, with an eye toward more predictive analytics and possibly AI-enabled tools to anticipate patient issues before they escalate. Beyond technology, Viemed is broadening its scope with sleep therapy, maternal health, and other home-care offerings, and is using targeted acquisitions and partnerships (such as value-based care platforms) to accelerate that shift. Overall, the company appears to be investing thoughtfully in both digital capabilities and service diversification, which can deepen its moat if executed well.

Summary

Viemed Healthcare combines steady top-line growth, consistent profitability, and a conservative balance sheet with a focused competitive niche in home respiratory care. It generates reliable operating cash and reinvests heavily into its equipment and technology infrastructure, signaling a long-term growth mindset rather than short-term cash maximization. Its high-touch clinical model, technology platform, and payer and provider relationships give it a meaningful edge in its chosen segment. The main uncertainties lie in its dependence on reimbursement frameworks, the challenge of scaling a labor-intensive care model, and the need to successfully expand into adjacent home-care verticals. Overall, this looks like a disciplined, specialty-focused healthcare operator that is using technology and selective expansion to deepen and broaden its role in the home-care ecosystem.

NEWS

November 5, 2025 · 4:30 PM UTC

Viemed Healthcare Announces Third Quarter 2025 Financial Results

Read more

October 21, 2025 · 6:15 PM UTC

Viemed Healthcare Announces Third Quarter 2025 Earnings Conference Call Details

Read more

September 23, 2025 · 5:00 PM UTC

Viemed Healthcare Announces Completion of Share Repurchase Program

Read more